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KSU IRB Approval Form – updated 8.28.19 (replaces all previous versions and must be used) 
 
 
INSTITUTIONAL REVIEW BOARD APPLICATION 
 





___Check here for a Request for Exemption 
 
__X_Check here for an Expedited Review [IRB Reviewers may recommend a Full Board Review] 
 
Status of Primary Investigator: 
 
_X__Faculty              ___Staff                     ___Student 
 
Students as the Primary Investigator (PI) and their Faculty Advisors 
Students (graduate and undergraduate) must have a faculty advisor complete the last page of 
this form and submit all documents from the faculty advisor’s KSU email address. Students 
must also use their KSU email address in all IRB correspondence.  
 
By submitting this form, you agree that you have read KSU’s Federal-wide Assurance of 
Compliance and agree to provide for the protection of the rights and welfare of your research 
participants as outlined in the Assurance.  You also agree to submit any significant changes in 
the procedures of your project to the IRB for prior approval and agree to report to the IRB any 
unanticipated problems or adverse events involving risks to subjects or others. 
 
Title of Research  
The Phoenix Sign: Is it due to vasodilation?  Blinded prospective comparing the 
effects of papaverine to lidocaine without epinephrine 
 
 
Start Date is date of IRB approval    Proposed start date: ____3/1/2020__________ 
 
*The official start date for research is the date the IRB approval letter is issued.  Research 
activities may not begin prior to final IRB approval.  Studies should be submitted well in advance 
of the proposed start date to allow for processing, review, and approval.  If you have not received 
a letter from the IRB in 10 business days of submission, please call or email requesting status 
update. 
 
Is your research being funded in any way?  ___Yes* __X_ No  
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All IRB correspondence goes only to the primary investigator (PI) and advisors are 





Telephone:  Email: sbarre52@kennesaw.edu 
  
FOR RESEARCH CONDUCTED BY STUDENTS AS THE PRIMARY INVESTIGATOR, GO 
TO THE LAST PAGE OF THE APPLICATION FORM TO ENTER REQUIRED FACULTY 
ADVISOR INFORMATION. 
 
Co-Investigator(s) who are faculty, staff, or students at KSU 
 
 
Co-Investigator(s) who are NOT employees or students at KSU: Please 




Stephen L. Barrett, D.P.M., FACFAS FAENS 
Molecular and Cellular Biology 
832-524-7254 
Name: Kerry McCardel 















Additional Names (include status and email):  
Adam Kahn Student   akhan42@students.kennesaw.edu 
 
Name: Sequioa DuCasse, D.P.M., MS 
Email: sducasse.dpm@gmail.com 
Home Institution: US Neuropathy Centers, LLC 
Name: Porscha Bailey, D.P.M. 
Email: porschaba@gmail.com 
Home Institution: US Neuropathy Centers, LLC 
Additional Names (include email and home institution):  
Nia Mitchell  US Neuropathy Centers LLC   nia.m.mitchell@gmail.com 
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ALL researchers listed on this application MUST have completed CITI training BEFORE 
an IRB Approval will be provided. 
 
Visit http://research.kennesaw.edu/irb/citi-training.php for additional information about CITI 
training, how to choose the right course, and how to create a profile. ALL KSU 
faculty/staff/students MUST use their KSU provided email address on all correspondence. 
 
NOTE: It is each researcher’s responsibility to ensure that the CITI Certificate does not 
expire during the course of the approved study. Failure to maintain a current certificate 
will invalidate your approval. Please use your KSU email address on your CITI profile 
and make sure your profile name matches the one provided above. 
 
Does your research involve minors?  ___Yes __X_No  
See item number 5 below for parental consent and minor assent information. See 
http://research.kennesaw.edu/irb/consent-templates.php for forms and information. 
 
  
Will this research involve COLLABORATION with ANOTHER INSTITUTION? 
 
___Yes __X_No, go to question 1 
 
If yes, provide the name of the Institution __________________________________ 
 
Has the other Institution conducted an IRB review of the study? 
 
___No ___Yes – Send that review with this approval form to the KSU IRB. 
 
1. Prior Research 
 
Have you submitted research on this topic to the KSU IRB previously? _X__Yes* ___ No 
 
*If yes, list the date, title, name of investigator, and study number:  
 
Study 20-143: Sonographically Guided Infiltration of Low dose 
infiltration of 1% lidocaine as a Predictor for the Efficacy of 




See http://research.kennesaw.edu/irb/application-tips.php for detailed explanations of 
questions 2-8. Provide complete sentences with sufficient information for an IRB review. 
 
2. Description of Research  
a. Purpose of and anticipated findings for this study:  
A neurological phenomenon has been observed clinically that when after a 
small amount of 1% lidocaine (usually less than .5cc’s) has been infiltrated 
adjacent to the Common Fibular (Peroneal) nerve under sonographic 
guidance, in patients with drop foot, or significantly weakened motor 
potentials of the lower extremity dorsiflexors (Extensor Hallucis Longus 
(EHL), Tibialis Anterior (TA), and Extensor Digitorum Longus (EDL)), the 
patient will regain partial or full dorsiflexion temporarily during the effect of 
this nerve block.  This has been named the Phoenix Sign, in reference to 
4 
 
KSU IRB Approval Form – updated 10.2.19 (replaces all previous versions and must be used) 
ancient Greek folklore, as the non-functioning nerve (like the bird) becomes 
functional due to the effect of lidocaine, similar in a way that the mythical bird 
rose from the ashes.  This sign has significant benefit to the diagnosis and 
assessment of Common Fibular (Peroneal) nerve palsy as clinically when a 
nerve does not manifest a Tinel’s or Provocation sign it is believed that the 
nerve damage is so severe that peripheral nerve decompression will not 
likely benefit the patient.  However, when a patient manifests a “positive 
Phoenix sign” the prognosis has been greater than 90%--that the patient will 
gain improvement in motor function of the dorsiflexors of the lower extremity 
after surgical decompression.  Thus, many patients with this crippling 
condition are not receiving definitive treatment because of the inability of 
standard clinical work-up and diagnosis. A “positive Phoenix sign” also 
differentiates a focal nerve compression peripherally versus a central CNS 
manifestation. It is hypothesized that this observation of improved nerve 
function is due to the vasodilatory nature of the local anesthetic. By 
comparing the block given with lidocaine versus papaverine (a known 
vasodilator), the vasodilation hypothesis can be tested.  The purpose of this 
study is to help determine if this is a valid explanation for the phenomenon. 
 
b. Nature of data to be collected (interview (includes focus groups), online or hardcopy 
survey, observations, experimental procedures, etc.): 
This study is doubly blinded so that the clinician and the patient do not know 
what infiltrate is being used.  They will be consented to have either an 
infiltration of lidocaine, or papaverine.  All of these compounds are FDA 
approved for human use, and all are commonly used in clinical practice.  If 
the “Phoenix Sign” is observed in the both the lidocaine and papaverine arms 
it would provide compelling evidence that this phenomenon is due to the 
vasodilation effect of the local anesthetic.  A comparison could lend credence 
to solely using papaverine clinically. 
 
Data that will be collected: 
1. Pre-infiltration EHL, TA and EHL strength assessment as measured 
clinically on a 1-5/5 scale and with a dynamometer. 
2. Pre-infiltration pain assessment as measured on a 1-10 VAS pain 
scale 
3. Post-infiltration at 4 minutes after injection EHL, TA and EHL strength 
assessment as measured clinically on a 1-5/5 scale and with a 
dynamometer 
4. Post-infiltration pain assessment as measured on a 1-10 VAS pain 
scale 
5. Length of duration of the effect-if any 
 
 
c. Data collection procedures: (include information on how consent will be obtained, how 
links will be provided, where interviews will be conducted, audio or video taping, etc.). 
Note: student email addresses are FERPA protected. Student email addresses, 
grades, or work cannot be collected without student consent and IRB approval. 
Informed Consent will be obtained in the clinical setting from patients 
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d. Survey instruments to be used (pre-/post-tests, interview and focus group 
questionnaires, online surveys, standardized assessments etc.). Attach all survey 





e. Method of selection/recruitment of participants:   
Refer to the KSU Mass Email policy on the use emails to faculty/staff.  For student 
recruitment via email, please also follow these mandatory instructions.   ALL 
recruitment materials (flyers, emails, posters, etc.) MUST include your IRB Approval 
Study # and a statement that your study has been reviewed and approved by KSU’s 
IRB. 
Subjects will be recruited from our existing clinical practice. 
f. Participant age range: __18-85__  Number: _20___   
        
       Sex: __Males __ Females or 20__Both 
 
g. Incentives, follow-ups, compensation to be used: (e.g., Gift cards, course credit, etc.). 
Please visit HERE on our website for guidelines on participant incentive payments.  
No incentives will be given to the subjects 
 
3.  Risks 
Describe in detail any psychological, social, legal, economic, or physical risk that might occur 
to participants.  Note that all research may entail some level of risk, though perhaps minimal.  
According to the federal regulations at §46.102(i), minimal risk means that the probability and 
magnitude of harm or discomfort anticipated in the research are not greater in and of 
themselves than those ordinarily encountered in daily life or during the performance of routine 
physical or psychological examinations or tests. 
 
_X_ There is minimal risk (if selected, must be reflected within consent documents) 
 
__ There is more than minimal risk (requires full explanation below and in consent documents) 
 
Anticipated risks include (if selected, specific potential risks must be incorporated into 




If more than minimal risk is anticipated, describe your method for handling risk. 
 
 
4.  Benefits 
 
Federal Guidelines and University policy require that risks from participation be outweighed by 
potential benefits to participants and/or humankind in general.  
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a. Identify potential benefits to participants resulting from this research (It is possible that 
there are no direct benefits or possible specific benefits, either must be reflected in the 
consent documents):  
 
As a positive “phoenix sign” is highly predictive of a positive result after surgical 
peripheral nerve decompression surgery the subject will have the benefit of an 
additional level of diagnosis and assessment of their particular level of nerve 
status or function.   
 
b. Identify benefits to humankind in general resulting from this research. While there may 
be no potential benefits to participants there must be some benefit to humankind in 
order to receive IRB approval. Please include these benefits in the consent documents: 
 
There are many patients who suffer from drop foot due to an entrapment of the 
Common Fibular (Peroneal) nerve who are told that there is nothing that can be 
done for them to restore their function, and that only bracing with an ankle foot 
orthosis can be done.  Drop foot is a crippling condition, that in many cases can 
be completely reversed, that subjects the patient to not only a decreased quality 
of life, but increased falls—which have a very high level of mortality in the aging 
population. Validation of the hypothesis could lead to wider clinical 
implementation affording patients additional diagnostic data. 
 
 
5.  Informed Consent  
 
All studies of human participants must include informed consent (see IRB approved 
templates).  Consent may require a signature or may simply require that participants be 
informed.  Minor participants must receive an assent form in conjunction with parental consent 
(see IRB approved templates). If deception is necessary, please justify and describe, and 
submit debriefing procedures.   
 
What is the consent process to be followed in this study?  Submit your consent form(s) with the 
application as a separate document(s). 
 
See attached consents  
 
6. Online Surveys (For all electronic surveys, you must submit a link to the final version 
of the survey.) 
 
Will you use an online survey to obtain data from human participants in this study? 
Check all that apply. 
 
_X_ No.  If no, skip to Question 7 below. 
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a. How will online data be collected and handled?  Select one and add the chosen 
statement to your consent document. 
 
__ Data collected online will be handled in an anonymous manner and Internet  
     Protocol addresses WILL NOT be collected by the survey program.  
 
__ Data collected online will be handled in a confidential manner (identifiers will be 
     used), but Internet Protocol addresses WILL NOT be collected by the survey  
     program.  
 
__ Data collected online will be handled in a confidential manner and Internet  
     Protocol addresses WILL be collected by the survey program.  
  
b. Include an “I agree to participate” and an “I do not agree to participate” answer at the 
bottom of your consent document.  Program the “I do not agree to participate” statement 
to exclude the participant from answering the remainder of the survey questions (this is 
accomplished through "question logic" in Survey Monkey or “skip logic” in Qualtrics).   
 
Ensure that the online consent document is the first page the participant sees after clicking on 
the link to your online survey.    
 
Although you may construct your own consent document, see the IRB approved Online Survey 
Cover Letter template (http://research.kennesaw.edu/irb/consent-templates.php), which 
contains all of the required elements of informed consent that must be addressed within any 
online consent document. 
 
7.  Vulnerable Participants 
 
Will minors or other vulnerable participants (e.g., prisoners, pregnant women, those with 
intellectual disabilities) be included in this research?   
 
__Yes.  Outline procedures to be used in obtaining the agreement (parental consent, assent or 
guardian consent) for vulnerable participants.  Describe plans for obtaining consent of the 
parent, guardian, or authorized representative of these participants.  For research conducted 
within the researcher’s own classroom, describe plans for having someone other than the 




_X_ No.  All studies excluding minors as participants should include language within the 
consent document stating that only participants aged 18 and over may participate in the study. 
 
8.  Future Risks   
 
How are participants protected from the potentially harmful future use of the data collected in 
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a. Describe measures planned to ensure anonymity or confidentiality. Studies can only be 
considered completely anonymous if no identifying information is collected; therefore, a 
cover letter must be used in place of a signed consent form. 
 
At the time a person becomes a patient in our practice, they are offered the 
opportunity to be part of clinical research.  They also have the option to not 
participate.  The form is attached that they are given at the time of them 
becoming a new patient.  If they give this general consent, they allow us to 
report data without anonymity, but will have additional informed consent for 
this study.  That consent is attached with this application 
  
b. Describe methods for storing data while study is underway.  Personal laptops are not 
considered secure.  
 
Data will be kept in our encrypted electronic medical record keeping system, and 
patient data will only be referenced to by non-identifying initials, age, and sex in 
any reporting of the data. 
 
 
c. List dates and plans for storing and/or destroying data and media once study is 
completed.  Please note that all final records relating to conducted research, including 
signed consent documents, must be retained for at least three years following 
completion of the research and must be accessible for inspection by authorized 
representatives as needed. 
  
Data will be stored for a minimum of 7 years or as directed by any authoritative 
body participating in the research. 
 
    






9.  Illegal Activities 
 
Will collected data relate to any illegal activities? __Yes* _X_No   
This includes asking about illegal activities from participants or surveys containing any 
reference to illegal activities (e.g., questions requesting information about witnessing illegal 
behaviors that others have engaged in, minors drinking or using drugs, or any illegal drug use 
or violence of any nature that would result in legal action). 
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Is My Study Ready for Review? 
 
Every research protocol, consent document, and survey instrument approved by the IRB is 
designated as an official institutional document; therefore, study documents must be as 
complete as possible.  Research proposals containing spelling or grammatical errors, missing 
required elements of informed consent (within consent or assent documents), not addressing 
all questions within this form, or missing required documents will be classified as incomplete.   
 
All studies classified as incomplete may be administratively rejected and returned to the 
researcher and/or faculty advisor without further processing.   
 
If you are a non-KSU researcher wishing to recruit participants from the KSU campus, please 
follow these instructions:  https://research.kennesaw.edu/irb/international-research.php 
 
Student researchers make sure that your faculty advisor completes the following page 
and sends all study related material from their KSU email address to 
irb@kennesaw.edu. Failure to follow this procedure will result in a significant delay in 










RESEARCH CONDUCTED BY UNDERGRADUATE AND GRADUATE 
STUDENTS AS PRIMARY INVESTIGATORS 
All undergraduate and graduate students who will be acting as the Primary Investigator must 
be under the direct supervision of a faculty advisor. The faculty advisor must review the IRB 
application materials and agrees to supervise the student’s proposed human subject research 
project by completion and submission of this routing sheet.   
 
All application materials must be submitted by the faculty advisor from their KSU email address 
to irb@kennesaw.edu. Students may not submit their materials to the IRB for the first review; 
however, subsequent revisions can be sent directly to irb@kennesaw.edu with a cc to your 
advisor and MUST come from your KSU provided email account. 
 
FOR RESEARCH CONDUCTED BY STUDENTS OR NON-FACULTY STAFF.  This study, if 
approved, will be under the direct supervision of the following faculty advisor who is a member 
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 Department:  




By checking the items below and submitting all materials from your KSU email, the faculty 
advisor for this project attests the following: 
 
___I have personally reviewed each of my student’s IRB application documents (approval 
request, exemption request, informed consent documents, child assent documents, survey 
instruments, etc.) for completeness, and all documents pertaining to the conduct of this study 
are enclosed (consents, assents, questionnaires, surveys, assessments, etc.) 
 
 ___ I have completed the Social/Behavioral Research course (Biomedical version only for 
medical/biological human studies) CITI training course in the ethics of human subject research 
within the past three years as have all researchers named within this application. 
 
___I approve this research and agree to supervise the student(s) as the study is conducted. 
 
 
Date:  _________ 
 
 
 
 
 
